Alkermes (ALKS) Cash & Equivalents (2010 - 2026)
Alkermes (ALKS) posted quarterly Cash & Equivalents of $511.5 million for Q2 2026, down 1.86% year-over-year from $521.2 million in Q2 2025, and up 45.51% quarter-over-quarter from $351.6 million in Q1 2026.
Alkermes (ALKS) Cash & Equivalents (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash & Equivalents for 17 consecutive years, with $511.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Equivalents fell 1.86% year-over-year to $511.5 million; the TTM figure through Jun 2026 stood at $511.5 million (down 1.86% YoY), while the FY2025 annual figure was $388.6 million, up 33.46% from the prior year.
- Cash & Equivalents improved to $511.5 million in Q2 2026 per ALKS's latest filing, from $351.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $665.8 million in Q2 2023 and bottomed at $254.6 million in Q2 2022.
- Historically, Cash & Equivalents has averaged $423.2 million across 5 years, with a median of $398.0 million in 2024.
- Annual changes were most pronounced in 2023 — Cash & Equivalents surged 161.46% — and 2024, when it tumbled 38.82%.
- Alkermes' Cash & Equivalents stood at $292.5 million in 2022, then surged by 56.41% to $457.5 million in 2023, then tumbled by 36.36% to $291.1 million in 2024, then jumped by 33.46% to $388.6 million in 2025, then surged by 31.64% to $511.5 million in 2026.
- Business Quant data shows ALKS's Cash & Equivalents at $511.5 million in Q2 2026, $351.6 million in Q1 2026, and $388.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 511.53 Mn |
| Mar 31, 2026 | 351.55 Mn |
| Dec 31, 2025 | 388.57 Mn |
| Sep 30, 2025 | 616.45 Mn |
| Jun 30, 2025 | 521.20 Mn |
| Mar 31, 2025 | 399.81 Mn |
| Dec 31, 2024 | 291.15 Mn |
| Sep 30, 2024 | 396.29 Mn |
| Jun 30, 2024 | 535.15 Mn |
| Mar 31, 2024 | 420.75 Mn |
| Dec 31, 2023 | 457.47 Mn |
| Sep 30, 2023 | 647.71 Mn |
| Jun 30, 2023 | 665.80 Mn |
| Mar 31, 2023 | 321.40 Mn |
| Dec 31, 2022 | 292.47 Mn |
| Sep 30, 2022 | 263.96 Mn |
| Jun 30, 2022 | 254.65 Mn |
| Mar 31, 2022 | 282.56 Mn |
| Dec 31, 2021 | 337.54 Mn |
| Sep 30, 2021 | 310.44 Mn |